Abstract
Background
The human body is a highly integrated biological system in which the gut flora wields regulatory control beyond simple digestion. Intestinal bacteria control neuronal and behavioral processes via the gut–brain axis; microbial gamma-aminobutyric acid (GABA) synthesis seems to be an essential controller of sleep and central nervous system activity. Increasing data show that neuroactive substances produced from bacteria influence mental health results, circadian rhythm, and sleep structure.
Summary
This review investigates the function of gut-derived GABA in sleep control, the part that particular bacterial taxa play, and the translational value of salivary GABA as a non-invasive indicator. Literature discussing microbial pathways for GABA production, gut–brain signalling mechanisms, food modulation, and ELISA-based salivary GABA determination was reviewed. Important GABA-producing genera including Lactobacillus, Bifidobacterium, and Faecalibacterium prausnitzii were investigated. Available data indicates that gut bacteria may contribute up to thirty percent of systemic GABA; metabolites of gut microbes like butyrate improve GABAergic signalling via epigenetic and receptor-mediated pathways. Diets high in probiotics and fermentable fibre are continuously linked to better sleep quality, less sleep latency, and greater sleep continuity. Using ELISA, salivary GABA levels between 0.1 and 1 µmol/L can be measured and show circadian fluctuation, thereby favoring saliva as a useful substitute for total neurochemical activity.
Key Message
Salivary GABA is a promising, drug-free biomarker connecting CNS performance, sleep regulation, and gut microbial activity. Its non-invasive character permits extensive clinical and community-based study, therefore supporting longitudinal monitoring of gut–brain interactions. Integration of psychobiotic treatments, AI-guided diet, and point-of-care biosensors may eventually change the stomach to be an organ.
Introduction
The Gut Network: Microbial Influence Beyond Digestion
‘The human body is a meticulously balanced ecosystem, wherein gut microbiota constitutes a complex and abundant microbial population within the gastrointestinal tract, playing a pivotal role in controlling host health and influencing disease susceptibility’. 1 GABA has earned the title ‘peacekeeper neurotransmitter’ due to its role in maintaining neural equilibrium, suppressing overstimulation and promoting emotional and cognitive stability through inhibitory signalling. Well beyond a mere symbiotic relationship, this complex microbial community, sometimes metaphorically referred to as our ‘second genome’ or ‘second brain’, coordinates an array of vital physiological activities, such as regulation of metabolism, development of the immune system and important protection against pathogens.2, 3 Current advances in science continue to reveal the omnipresent and dynamic impact of gut microbiota, especially through its complex and bidirectional communication with the central nervous system, a complex bidirectional interaction collectively referred to as the gut–brain axis.4, 5 Such an advanced neurobiological interface underscores the revolutionary appreciation that microbial inhabitants have a deep systemic effect, far from being restricted within the borders of the digestive tract, and provides new avenues for therapeutic investigations.6, 7
The disruption of the bacterial community was a causative factor in the etiology of complex disorders such as neurological disorders, immune disorders, metabolic disorders and gastrointestinal disorders. A recent report further indicated the common microbial signatures responsible for these diseases, necessitating more thorough research. For example, Prevotella copri was previously identified to be more abundant in T2D and rheumatoid arthritis patients than in healthy controls, potentially because of its immune-relevant function in pathogenesis. In more recent times, dysregulation of the gut-brain axis has been shown to play a role in the etiology of various neurological disorders such as Alzheimer’s disease (AD), autism spectrum disorder (ASD) and mood disorders. 8 Gut aging is correlated with decreased levels of the beneficial commensal microbes, which regulate the growth of pathogens and intestinal barrier integrity by producing mucus and lipid metabolites (e.g., SCFAs), leading to inflammatory diseases in older people. The changes of the gut microbiota in older people are correlated with higher rates of enteric diseases such as colon cancer, pathogens like CDI and other bowel diseases. 9
Gut-brain axis (GBA) or bidirectional communication between gut microbiota and brain affects physiology as well as behaviour by three distinct mechanisms. Neural pathway is predominantly the enteric nervous system (ENS) and vagus nerve. Endocrine pathway, on the other hand, modulates the neuroendocrine system of the brain, specifically hypothalamus-pituitary-adrenal (HPA) axis and immunological pathway. Some changes in the gut microbiota may cause obesity by modulating the metabolic processes and food intake of the host via GBA. As a result, new treatments of the gut microbiome, that is, faecal microbiota transplantation and probiotics and prebiotics supplementation, can be a future therapy for obesity. 10 Social stress has also been found to influence the microbiota by decreasing microbial diversity, such that the relative abundance of Bacteroides spp. and Lactobacillus spp. goes down, while bacteria in the genera Clostridium rise, with behaviour-mediated effect through microbiota, as shown in Table 1. Other forms of stress like restraint stress, assessed in adulthood, have been shown to change the relative composition of the different groups of bacteria (i.e., decrease in Lactobacillus genus in colonic mucosa). Additionally, Oscillospira, Lactobacillus, Akkermansia and Anaeroplasma genera are impacted in rats that are subjected to a model of post-traumatic stress disorder. Extended exposure to a restraint stressor also decreased short-chain fatty acids (SCFAs), but these increased in infection mice. While fewer human studies are available, the impact of stress on microbiota diversity also seems to be comparable to findings in preclinical studies. 11 There are four major parts in this review. Section 1 stresses the microbiological sources and regulatory impact of GABA on neuronal signalling as well as its physiological function in the gut-brain axis. Section 2 investigates GABA’s transport processes, including its movement over biological barriers and its likely occurrence in saliva as a quantifiable biomarker. Three describes the analytical detection methods employed for counting salivary GABA, emphasising ELISA-based techniques. Section 4 last emphasises the clinical ramifications of gut-derived GABA by noting its relevance in mental health, neurological illnesses and future diagnostic points of view.
GABA-producing Gut Microbes, Dietary Sources, Sample Type and Quantification. 18
Balancing the Brain: GABA’s Role in Neural Inhibition
Gamma-Aminobutyric Acid (GABA), originally discovered by Roberts in 1986, is the major inhibitory neurotransmitter of the human brain. GABA is responsible for the stability of equilibrium between neuronal inhibition and excitation. 12 GABA is produced from glutamate by the enzyme glutamic acid decarboxylase (GAD) and is subsequently catabolised to succinate by the sequential activity of GABA transaminase (GABA-T) and succinic semialdehyde dehydrogenase (SSADH). 13 Within the central nervous system, GABA decreases the excitability of neurons by 20% to 40%, thus regulating information processing. In the hippocampus, the GABAergic interneurons constitute 15%–20% of all neurons. Approximately one-third of the interneurons target the peri somatic region of pyramidal neurons. Individual GABAergic interneurons’ axonal length is generally two to four times shorter in comparison to CA3 pyramidal cells and varies significantly with the subtype of the interneuron. 14 Some of the papers mentions that the GABA works both as an inhibitory and excitatory neurotransmitter. 15
There are two types of GABA receptors present in our body and they are GABAA (Ionotropic) and GABAB (Metabotropic). Ionotropic receptor is also known as ligand gated ion channel, which opens the chloride channel when the GABA binds to the receptor and causes hyperpolarisation of the receptor, which inhibits the firing of neurons. Metabotropic receptors are known as G protein coupled receptor, which opens potassium channel and inhibits calcium channel. This will result in inhibitory action on the neurons. Five separate protein components make up GABAA receptors, therefore known as subunits. α (alpha), β (beta), γ (gamma) and δ (delta) are the names of these subunits; they come together to produce a complicated architecture. Every one of these subunit kinds also exists in several forms, which further broadens the construction of GABAA receptors. Different regions of the brain contain several kinds of GABAA receptors. Receptors containing α1 and γ2 subunits, for instance, are usually located at synapses, the tiny gaps between nerve cells where signals are quickly passed. Fast and short-term (phasic) inhibition is aided by these receptors. Conversely, receptors with α4, α5, α6 and δ subunits are discovered external or close to the synapses (extra synaptic or peri synaptic zones). Helping to regulate the overall activity of the brain, these receptors are more sensitive to GABA and engage in ongoing (tonic) inhibition. 16
Literature Review.
Following GABA’s Passage Through Blood and Saliva
Mostly produced from decarboxylation of glutamate, gamma-aminobutyric acid (GABA) can come from gut bacteria with glutamate decarboxylase (GAD) genes as well as from host neurons. Through carrier-mediated transporters such as GAT1–4 and the betaine/GABA transporter (BGT-1), microbiota-derived GABA may travel across the intestinal epithelial barrier and influence CNS function.
Peripheral GABA signals created in the gut may affect central neural pathways linked with emotional and stress control thanks to this gut–brain axis communication. Changes in central autonomic output can also modify salivary secretion and the diffusion of little neuroactive chemicals such as GABA and its derivatives via efferent feedback loops, as shown in Figure 2.
Inhibition Mechanism of GABA.
Flowchart of GABA Circulation into Blood and Saliva. 22
Emergent research indicates that salivary GABA represents a bidirectional neurochemical interaction between the central and intestinal regions. GABA carried across the blood–brain and blood–salivary barriers might operate as a marginal indicator of gut-brain activity. A key mediator of this axis is the vagus nerve: microbiota-derived GABA can activate vagal afferents, thereby modulating hypothalamic and limbic responses. Gut-derived GABA influences sleep regulation by enhancing parasympathetic (vagal) signaling to the central nervous system, as shown in Figure 1. 17
Analytical advancements have made measuring GABA and related substances in biological media more doable. Chen et al. (2025) created a quick and sensitive HPLC-MS/MS technique for the simultaneous quantitative analysis of imidazole-derived GABA receptor agonists—etomidate, metomidate, propoxate and isopropoxate—in mouse blood, which provides high accuracy and low detection limits appropriate for pharmacokinetic analysis. Using high-performance liquid chromatography, Upmanis et al. (2024) classified phenibut-containing nootropic formulations as well, highlighting the need for accurate GABAergic agent quantification in complicated samples. Using UPLC-MS/MS, Blanco-Ces et al. (2025) quickly quantified gamma-hydroxybutyrate (GHB)—a GABA-related metabolite—in hair, stressing long-term traceability in biological monitoring. Complementary derivatisation and mass-spectrometric approaches by Douša et al. (2016) and Mengerink et al. (2002) improved analytical sensitivity and adduct stability, whilst Song et al. (2012) showed in-vivo neurochemical monitoring of several neurotransmitters through benzoyl-chloride derivatisation combined with LC-MS/MS.
In essence, the gut microbiota acts as a dynamic regulator of sleep and CNS function via the gut–brain axis; these impact transporter expression and vagal signalling; and advanced analytical tools enable us to observe in saliva the neuroendocrine feedback and the ensuing peripheral GABA changes. Continued perfecting of LC-MS/MS and derivatisation methods, as demonstrated by Chen et al. (2025) and others, will improve the sensitivity and dependability of salivary GABA. as a possible indicator of gut-brain axis.
GABA is a water-soluble molecule but it cannot cross the intestinal lining because of the tight junctions. It can be absorbed by the body carrier mediated protein like proton coupled amino acid transporters and, in some cases, an increase in the intestinal permeability can also transport the GABA molecule to the blood. 19 GABA passes through the portal circulation, that is, blood from intestine to liver. Some material may be metabolised in the liver; others bypass hepatic metabolism and enter the systemic circulation. Plasma GABA concentrations have been discovered following probiotic supplementation or GABA rich fermented diets. 20 GABA is carried in the blood and is circulated in the tiny blood vessels called capillaries, present beneath the tongue. These capillaries have a thin wall and act as a filter in which a small molecule like GABA can pass through, so this how the GABA is mixed with the saliva. It reaches saliva by carrier mediated transport where the protein carries it to the saliva. 21
Numerous studies demonstrate that GABA synthesised by gut microorganisms is detectable in saliva, indicating a possible avenue for further investigation into the role of GABA in the human body. 23 Disorders like insomnia can be studied elaborately when the production of GABA is fully understood. Medical conditions like epilepsy occur due to a reduction in the GABA levels in the human body, so it is important to pursue the functions and quantification of GABA which is produced by the gut microbe. 24 Epilepsy is a serious medical condition; if it is left untreated, it may result in SUDEP (sudden unexpected death due to epilepsy). There are drugs like GABA enhancers which promote the sensitivity of the GABA-A receptor, and they are Benzodiazepines, Barbiturates and Z drugs (non-benzodiazepines), but long-term usage of these drugs may result in dependence. The patient may not feel calm or they cannot fall asleep due to the inability of the receptor to produce the required amount of sensitivity without the drug to produce the inhibitory action. 25 Similarly, in sleep diseases, GABA is involved, and it is regarded as the second most vital factor that is responsible for initiating and sustaining sleep, following melatonin. 26 Most of the sleep diseases, including insomnia and REM (Rapid Eye Movement) sleep behaviour disorder, have been linked to GABAergic dysfunction. 27 The understanding of GABA’s interaction with sleep is, thus, an essential component of this review. Gut bacteria play an important role in this process by synthesising GABA from fermentation of dietary substrates, a natural biological process that fascinates clinicians and researchers alike. 28 Regulation and comprehension of this microbial pathway might assist in attaining optimal physiological function, such as regulated sleep. Biological augmentation of GABA levels, by Gut microbiota modulation, could be a potential non-pharmacological choice for the management of sleep disorders, particularly when compared to the use of traditional sleep medications, which tend to result in tolerance and dependence with long-term use. 29
Method
The review was carried out using a resource such as PubMed, EmBase, Google Scholar, Elsevier using the keywords ‘GABA’, ‘microbiota’, ‘saliva’, ‘ELISA’, ‘psycho biotics’, ‘salivary enzymes’, ‘HPLC’, ‘LCMS’, ‘Gut’, ‘Intestinal pathway’, ‘Neurotransmitters’, ‘Sleep induction’, ‘sleep pattern’, ‘Circadian cycle’, ‘Sleep cycle’, ‘Melatonin’. The articles published in the English language and after the year 2000 were included in the study. The review follows the PRISMA guideline for screening and selection of the articles, as shown in Figure 3.
PRISMA Flow Diagram of the Included and Excluded Studies.
Detection Tools and Techniques
There are many types of quantification of GABA in saliva but they are expensive, time consuming and require proper laboratory environment. Some of the commonly and widely used method for quantifying GABA in saliva are as follows:
High-performance Liquid Chromatography (HPLC)
The most frequently used and dependable technique for measuring γ-aminobutyric acid (GABA) in biological specimens, including saliva, is high-performance liquid chromatography (HPLC). HPLC is sometimes linked with fluorescence detection (HPLCFLD) to improve detection sensitivity, especially after derivatisation with reagents like ophthalaldehyde, which creates a fluorescent complex with GABA. 30 Or, for more accurate quantification and structural elucidation, one may use UV detection (HPLCUV) 31 or tandem mass spectrometry (HPLCMS/MS). 32 Collecting saliva samples, centrifugation to eliminate cell debris, then derivatising GABA in the supernatant to improve detectability before injection into the HPLC system define the usual process. Subsequently, the compound’s retention time and signal intensity in the chromatogram are used for quantisation. This method is rather time-consuming, necessitates elaborate sample preparation techniques, including derivatisation, and needs pricey equipment and chemicals even if it offers excellent specificity and sensitivity.30–32
Liquid Chromatography–Mass Spectroscopy (LCMS)
The widely accepted gold standard for the quantification of small molecules like γ-aminobutyric acid (GABA) in biofluids, including saliva, is liquid chromatography–mass spectroscopy (LCMS). Unmatched sensitivity and specificity offered by this method makes it especially helpful for finding GABA at low physiological levels. 33 Usually, the sample preparation calls for protein precipitation or solid-phase extraction (SPE) to get rid of interfering compounds from saliva. Following this, the LCMS/MS system is fed with the sample, where GABA is quantified according to its typical mass to charge ratio (m/z). 34 Though LCMS/MS offers very precise and repeatable results, its usage is constrained by the high cost of equipment and the demand for trained technical staff to run and service the system. 35
Gas Chromatography–Mass Spectrometry (GCMS)
Though it is used less often because of the non-volatile nature of the compound, gas chromatography–mass spectrometry (GCMS) has also been investigated for the measurement of γ-aminobutyric acid (GABA). Normally, while using reagents like N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA), 36 a chemical derivatisation step is required to enhance the volatility of GABA and render it fit for GCMS analysis. Although GCMS is very sensitive, the derivatisation process is technically difficult, time consuming and brings variability that might compromise repeatability, 37 hence, it is not often utilised for regular saliva analysis of GABA. Therefore, although GCMS is still a potent analytical instrument in some research situations, it is not deemed perfect for clinical saliva testing applications. 38
Capillary Electrophoresis (CE)
Capillary electrophoresis (CE), another analytical method utilised for the measurement of γ-aminobutyric acid (GABA), is particularly appreciated for its capacity to distinguish ions according to their electrophoretic mobility inside small capillary tubes. Coupling with laser-induced fluorescence detection (CELIF) often enhances this technique and greatly raises sensitivity and detecting limits for low-abundance compounds such GABA. 39 CE’s low sample need is among its main benefits; therefore, it is particularly appropriate for research on limited saliva volumes. Though CE has advantages, it is linked with medium operating complexity and less frequently accessible in regular analytical facilities, hence restricting its broad use in clinical contexts for GABA analysis, as shown in Table 3.40, 41
Analytical Methods for GABA Quantification in Saliva. 45
Nuclear Magnetic Resonance (NMR)
Without derivatisation or separation, nuclear magnetic resonance (NMR) spectroscopy provides a non-destructive and direct way to detect γ-aminobutyric acid (GABA) by detecting its distinct molecular fingerprints. This method helps to preserve the integrity of the analyte 42 and calls for very little sample preparation. Because of its naturally low sensitivity, particularly when GABA is found in trace concentrations, NMR is less often used for saliva-based GABA analysis. Therefore, its real usage is confined to samples with great GABA concentrations or in locations where signal enhancement methods include cryoprobe technology or cutting-edge pulse sequences are accessible. 43 Moreover, the high expense of instrumentation and upkeep further limits its everyday use in typical clinical labs. 44
Enzyme-linked Immunosorbent Assay (ELISA)
The enzyme-linked immunosorbent assay (ELISA) is now a convenient and relatively inexpensive method for quantifying γ-aminobutyric acid (GABA) in saliva, providing a substitute for the more difficult chromatographic and spectrometric analyses. Its ease of use, comparatively low cost and suitability for high-throughput screening make ELISA an especially suitable method for clinical and epidemiological research involving large populations. 46 GABA salivary ELISA kits should involve minimal sample volume and follow a simple workflow, which usually includes saliva collection, centrifugation to harvest debris-free saliva, incubation of samples in pre-coated microplates, washing and detecting by a substrate–enzyme reaction. Such a simple format enables broad usage even in low-resource laboratories. 47 For saliva, ELISA’s strength is its non-invasive sampling, limiting participant stress and allowing for repeat measurement—particularly important in neuropsychiatric studies and children. 48 While ELISA is not as sensitive as LC-MS/MS or CE-LIF, advances in antibody avidity, signal amplification and calibration of assays have recently made detection much more accurate for low-abundance analytes such as GABA. 49
In addition, salivary ELISA analysis avoids the requirement for derivatisation and intricate extraction procedures, further reducing the analytic process. 50 Nevertheless, the specificity of ELISA can be affected by cross-reactivity with structurally related amino acids, and standardisation between different commercial kits is problematic. 51 Nevertheless, under valid validation and quality control, ELISA offers a scalable and effective method for routine salivary GABA determination in both clinical and research environments.
Critical Discussion
Salivary GABA is emerging as a convenient, non-invasive indicator of gut–brain axis function, enabling repeated sampling in both clinical and community settings. However, its reliability as a biomarker of central GABAergic tone remains debated.52–55
First, the correspondence between salivary and central GABA is still indirect. Gut-derived GABA and related metabolites influence neural circuits mainly through vagal and endocrine signalling, not direct diffusion across the blood–brain barrier.56–58 Therefore, salivary GABA likely reflects peripheral modulation rather than synaptic concentrations. Evidence from neurochemical monitoring by Song et al. (2012) and pharmacokinetic work by Chen et al. (2025) supports measurable systemic GABA activity, yet confirmatory central–salivary correlation studies are lacking.
Second, substantial inter-individual variability arises from factors such as diet, circadian rhythm, stress, oral microbiota, medication use and saliva flow rate. Standardised collection protocols—consistent timing, fasting state and controlled storage—are essential to reduce confounding, as emphasised by Upmanis et al. (2024) and Blanco-Ces et al. (2025).
Third, analytical specificity of ELISA remains a concern. Cross-reactivity with structurally similar compounds (e.g., glutamate, GHB) and matrix effects can bias results. Validation against chromatographic–mass spectrometric platforms such as LC-MS/MS and UPLC-MS/MS, described by Douša et al. (2016), Mengerink et al. (2002) and Zhang et al. (2024), is recommended to ensure accuracy.
In summary, salivary GABA holds promise as a peripheral, exploratory biomarker of gut–brain communication. Yet, its translation to clinical utility requires rigorous analytical validation, standardised pre-analytical methods, and concurrent measurement of plasma and central GABA to establish physiological relevance.
Results
The GABA quantification ELISA is a competitive binding assay. The sample or standard solution of 50–100 µL is first added to each of the respective wells of the 96-well plate. Next, the addition of a GABA–HRP enzyme conjugate to each well is done, and the endogenous GABA competes with the conjugated GABA for antibody binding. The plate is subsequently incubated at room temperature for 1 to 2 hours, allowing for adequate interaction. The plate is washed after incubation with 3 to 5 wash cycles to remove any unbound material. A TMB (3,3′,5,5′-tetramethylbenzidine) substrate is then added to trigger a colorimetric reaction, which develops within 10 to 30 minutes. The reaction is stopped using a stop solution, and sulfuric acid (H2SO4) is commonly used. Lastly, absorbance at 450 nm is read using a microplate reader, and the obtained values are used to interpolate sample concentrations from the standard curve. 65
Limitations
The ELISA assay to detect GABA is not without certain limitations59, 60. Its sensitivity might not be sufficient to pick up very minor changes in the level of GABA. Specificity is another issue, as assay antibodies might cross-react with structurally analogous molecules such as glutamate.61, 62 Variation between commercial kits further emphasises the importance of proper batch-to-batch standardisation and validation.63–66
Applications in Gut-brain Axis Research
Salivary GABA ELISA is being used more and more in translational research into the gut-brain axis, notably within the disciplines of nutritional neuroscience and psycho biotic therapy. For example, intake of GABA-producing probiotic strains like Lactobacillus rhamnosus has been linked with elevated salivary GABA, together with quantifiable positive effects on mood and emotional control. 67 The same has been proven with fermented food-based diets such as kimchi, miso and kefir, which have shown increases in peripheral GABA linked with improved sleep quality and decreased anxiety scores. 68 Additionally, psycho biotic trials have utilised salivary GABA as a non-invasive biomarker to quantify microbial-based interventions’ efficacy in influencing emotional control and resilience against stress, illustrating its increasing use in behavioural and mental health studies. 69
Benefits
Reason Behind Monitoring Salivary GABA
The potential to non-invasively measure GABA levels in saliva poses an attractive option in pushing forward with gut-brain axis research, particularly for assessing the effect of gut microbial metabolites on human neurological and behavioural endpoints. Saliva is a readily available biofluid that poses little risk and discomfort, thus allowing for frequent, real-time measurement. This makes it particularly ideal in studies incorporating dietary, probiotic and psycho biotic interventions in targeting mental health, sleep control and neurodevelopment. 70 Application of ELISA-based methods for salivary GABA measurement provides a balance between technical practicability and biological meaningfulness. In contrast to blood or CSF sampling, salivary sampling is not technically demanding or invasive, and ELISA does not require advanced machinery such as LC-MS/MS. This provides a low-cost, high-science tool with scalability and clinical applicability for translational research and public health screening. 71
Current Research Gaps
While salivary GABA testing is promising, a number of gaps in research detract from its broader use and standardisation. One limiting factor is that there is currently no generally accepted reference range for the level of salivary GABA in young healthy adults, making cross-study comparison and normative evaluations difficult. 72 Moreover, numerous studies employ non-validated or unreliable ELISA procedures, resulting in inconsistencies in sensitivity, specificity and matrix compatibility, which undermines reproducibility and generalisability of the results. 73 The majority of data on GABA-producing bacteria come from in vitro work, with little in vivo or clinical support for their effectiveness in substantially raising systemic or salivary GABA concentrations. 74 In addition, much remains unknown about salivary GABA and its relationship to neurological disorders such as epilepsy, mood disorders, or insomnia—although these disorders are in close association with GABAergic function. 75
Salivary GABA as a Tool for Personalised, Non-drug Sleep Enhancement
Recent research indicates that probiotic and dietary therapies can modulate levels of GABA and enhance sleep quality. 76 If salivary GABA significantly increases with particular probiotic diets or foods high in GABA (such as kimchi, kefir or GABA-fortified yogurt), this could serve as the basis for non-pharmacologic, individualised sleep treatments—especially useful in populations refraining from or resistant to pharmacologic therapy. Aside from favouring overall wellness, these methods might be included in tailored diet programs or psycho biotic treatments that increase peripheral GABA levels, enhancing onset and continuity of sleep. 77 These strategies fit into an emerging trend towards nutritional psychiatry, which focuses on dietary-based treatments of mental and emotional health.
Real-time Monitoring and Preventive Care
Regular salivary monitoring with ELISA or less complex alternatives can aid real-time monitoring of GABA changes in subjects who are experiencing lifestyle modifications, stress management protocols, or behaviour therapy. This can be especially useful in early diagnosis of sleep disorders such as insomnia or circadian rhythm dysregulation. Tracking gut-mediated neurochemical imbalance prior to the appearance of clinical symptoms. Offering low-risk, preventive interventions such as nutritional adjustments or prebiotic supplementation. 78 The accessibility of low-cost, portable kits for the quantification of salivary GABA has the potential to transform community-based mental health and wellness screening into a common component of preventive care.
Therapeutic Innovation in Nutrition and Psycho Biotics
Novel therapeutic approaches seek to tap into the gut microbiota to regulate GABA levels and maintain mental well-being. Some of these are GABA-producing probiotics and synbiotics that are undergoing clinical trials, chronobiotics that have been formulated to synchronise with the circadian rhythm for better sleep and postbiotic products with GABA or its precursors. More sophisticated solutions include microbial therapies engineered in the lab to colonise the gut and stably increase GABA levels. 79 This opens the door to precision psycho biotics, strains chosen not only for survival in the gut or adhesion but for their proven in vivo capacity to increase levels of GABA, quantifiable via non-invasive salivary assays.
Future Directions: Digital Integration and Kit Innovation
The future of salivary monitoring of GABA is in intelligent, software-linked diagnostics. A mobile-enabled system capable of combining digital technology with GABA monitoring may transform the management of gut-brain health. Apps recording intake of food, monitoring mood or sleep, and correlating dietary triggers with salivary GABA spikes would offer real-time, tailored advice. Paired with low-cost GABA sensor kits—like aptamer-based biosensors or colorimetric strips readable via smartphone cameras—these platforms would bypass the intricacy of ELISA testing. 80 These kinds of innovations would revolutionise both clinical and self-nutrition by allowing individualised food maps to naturally increase GABA levels, recommend users evidence-based foods and supplements that enhance GABA levels and create feedback loops to track intervention effects over time.
Persuading the Research and Clinical Community
Cumulatively, these advances suggest a mental health, sleep science and microbiota research paradigm shift. With the capacity to monitor GABA, a leading neurotransmitter in a saliva drop, through affordable kits, unlocks possibilities across disciplines, including multidisciplinary collaboration, which is critical in progressing GABA-based treatments. Clinical diagnosis provides the identification of neurological and psychological conditions associated with GABA dysregulation. Behavioural therapy is supportive by modifying lifestyle and mental health patterns. Nutritional sciences assist by investigating diet-based approaches to regulating GABA levels. Bioinformatics supports analysis of intricate gut-brain data, enabling the discovery of biomarkers and personalised advice. Lastly, precision psycho biotics are a new frontier, targeting well-documented gut strains that stimulate GABA production, and paving the way for personalised gut-brain medicine. 80
Discussion
Even with its potential, salivary GABA quantification has a number of drawbacks. One of the most significant drawbacks is the absence of globally acknowledged reference values for salivary GABA levels in healthy young adults, complicating interpretation and cross-study correlation. 81 Moreover, the differences in ELISA kit sensitivity and antibody specificity usually cause variability and potential cross-reactivity with structurally related amino acids such as glutamate and glycine. 82 Salivary GABA levels are also physiologically low, requiring extremely sensitive methods of detection and stringent handling of the sample to preclude degradation. 83 It is challenging to develop a direct and causal relationship between salivary levels of GABA and gut microbial GABA synthesis, as GABA bioavailability is regulated by intestinal uptake, metabolic processing in the liver and distribution to peripheral locations. 84 In addition, personal variability in gut microbiota composition, diet, stress and circadian rhythm can also profoundly affect salivary GABA levels, thus interfering with data interpretation. 85 Existing evidence is hindered by the dominance of in vitro and animal experiments with inadequate in vivo validation in humans for the efficacy of probiotics in raising systemic GABA. 86 Lastly, the procedural and cost complexity of ELISA attest to the imperative of creating simpler, cheaper and portable GABA detection devices for real-time and population-level use. 87
Conclusion
The present research emphasises the potential utility of salivary GABA measurement by ELISA as a non-invasive and effective tool for probing dynamic interaction between gut microbiota and neurochemical homeostasis in young adults. By targeting 18–25-year-old subjects, the protocol reduces age-related hormonal and metabolic confounders to permit more precise interpretation of microbiota-induced GABA changes. 88 Salivary sampling is nonpainful, repeatable and well-suited to large-scale or real-time monitoring, so it is particularly well-suited for both preventive and clinical health research. 89 Results of such studies can be a useful biomarker for quantifying the effect of probiotic or dietary intervention on central inhibitory tone. As one example, novel data indicate that GABA-producing psycho biotics like Lactobacillus brevis or Bifidobacterium dentium can increase systemic GABA levels, with downstream effects on sleep, stress and even seizure threshold.90, 91 In addition, this line of research provides the basis for the design of precision psycho biotic therapies, personalised diets or even GABA-enriched functional foods (e.g., yogurts or nuts) to promote brain health without drugs. 92 Notably, this model identifies several gaps in research—such as the absence of a gold standard salivary GABA reference range, scarce human studies correlating gut-derived GABA with systemic effects and the necessity of low-cost, simplified field-friendly GABA detection kits. These gaps may be overcome to enable the development of bioengineered probiotics, postbiotic products and AI-based nutritional apps that monitor and boost GABA naturally.93, 94 In summary, this research provides a translational platform between gut microbiome research and psychiatric investigation by highlighting the potential of salivary GABA-ELISA with significant implications for non-pharmacological treatments of sleep diseases, stress and mood disorders.
Footnotes
Abbreviations
GABA: Gamma-Aminobutyric Acid, CNS: Central Nervous System, PNS: Peripheral Nervous System, BBB: Blood Brain Barrier, ELISA: Enzyme-Linked Immunosorbent Assay, GI: Gastrointestinal, Git: Gastro-intestinal Tract, HPA axis: Adrenocorticotomic Axis of the Hypothalamus and Pituitary, SCFA: Short-Chain Fatty Acid, LPS: Lipopolysaccharide, GABAA: Gamma-aminobutyric acid Type A receptor, Gamma-aminobutyric Acid Type B Receptor; GABA B receptor, Cycle of Tricarboxylic Acid, LCMS/MS: Tandem Mass Spectrometry in Liquid Chromatography, PCR: Polymerase chain response, qPCR: Quantitative Polymerase Chain Reaction, OD: Optical Density, CFU: Unit creating a colony, GLUT: Transporter of Glutamate, BCA: Bicinchoninic Acid (Assay), ATP: Adenosine Triphosphate, Caco2: Line of Human Colorectal Adenocarcinoma Cells, REM: Accelerated Eye Movement, NREM: Non-Rapid Eye Movement, IgA: Immunoglobulin A, TNFα: Tumor Necrosis Factor Alpha, Interleukin6 (IL6), ROS: Reactive Oxygen Species, NO: Nitric Oxide, BDNF: Brain Derived Neurotrophic Factor, cAMP: cyclic adenosine monophosphate, AMPK: AMP: Activated Protein Kinase, mTOR: Mechanical Aim of Rapamycin, NFκB: Nuclear factor kappa light chain enhancer of activated B cells, ISCs: Cells of the Intestine, ESPs: Exopolysaccharides, TGFβ: Turning Growth Factor Beta, GPR: G-Protein-Coupled Receptor, KEGG: Kyoto Encyclopedia of Genes and Genomes, Firmicutes to Bacteroidetes Ratio: F/B Ratio, v/v: Volume per Volume, OD600: Optical Density at 600 nm, PBS: Phosphatel-Buffered Saline, HRP: Horseadish Peroxidase, TMB: 3,3′,5,5′Tetramethylbenzidine.
Acknowledgement
The author would like to thank the logistic and technical support rendered by JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, Tamil Nadu, India for supporting the study.
OpenAI has been used for formatting and grammatical check.
Authors’ Contribution
Rajamohamed H and Paul Mathi Vthana K did conceptual design.
Mica Isaac Anand acquired data.
Sameeha and Harun examined and interpreted data.
Edlin prepared the manuscript.
Deva Kumar S did the critical revision of the manuscript.
Statement of Ethics
Not required as it is a review article.
Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Funding
The authors received no financial support for the research, authorship and/or publication of this article.
ICMJE Statement
N/A.
Patient Consent
N/A.
Supplemental Material
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
